299 related articles for article (PubMed ID: 16364620)
21. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
22. Expression of the WASP verprolin-homologues (WAVE members) in human breast cancer.
Fernando HS; Davies SR; Chhabra A; Watkins G; Douglas-Jones A; Kynaston H; Mansel RE; Jiang WG
Oncology; 2007; 73(5-6):376-83. PubMed ID: 18509249
[TBL] [Abstract][Full Text] [Related]
23. HDAC6 expression is correlated with better survival in breast cancer.
Zhang Z; Yamashita H; Toyama T; Sugiura H; Omoto Y; Ando Y; Mita K; Hamaguchi M; Hayashi S; Iwase H
Clin Cancer Res; 2004 Oct; 10(20):6962-8. PubMed ID: 15501975
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and prognostic and predictive relevance of PRAME in breast cancer.
Doolan P; Clynes M; Kennedy S; Mehta JP; Crown J; O'Driscoll L
Breast Cancer Res Treat; 2008 May; 109(2):359-65. PubMed ID: 17624586
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer.
Mita K; Zhang Z; Ando Y; Toyama T; Hamaguchi M; Kobayashi S; Hayashi S; Fujii Y; Iwase H; Yamashita H
Jpn J Clin Oncol; 2007 Aug; 37(8):575-82. PubMed ID: 17675285
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival.
Gong YP; Yarrow PM; Carmalt HL; Kwun SY; Kennedy CW; Lin BP; Xing PX; Gillett DJ
Eur J Surg Oncol; 2007 May; 33(4):438-43. PubMed ID: 17125961
[TBL] [Abstract][Full Text] [Related]
27. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
29. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
30. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer.
Parr C; Jiang WG
Eur J Cancer; 2009 Jun; 45(9):1673-83. PubMed ID: 19328678
[TBL] [Abstract][Full Text] [Related]
31. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
[TBL] [Abstract][Full Text] [Related]
32. [Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis].
Li HX; Zh S; Zhang YH; Risberg B; Karlsson MG; Nesland JM
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):669-72. PubMed ID: 15777505
[TBL] [Abstract][Full Text] [Related]
33. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma.
Span PN; Sweep CG; Manders P; Beex LV; Leppert D; Lindberg RL
Cancer; 2003 Jun; 97(11):2710-5. PubMed ID: 12767082
[TBL] [Abstract][Full Text] [Related]
35. The role of growth differentiation factor-9 (GDF-9) and its analog, GDF-9b/BMP-15, in human breast cancer.
Hanavadi S; Martin TA; Watkins G; Mansel RE; Jiang WG
Ann Surg Oncol; 2007 Jul; 14(7):2159-66. PubMed ID: 17453295
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients.
Farmen RK; Nordgård O; Gilje B; Shammas FV; Kvaløy JT; Oltedal S; Heikkilä R
Breast Cancer Res Treat; 2008 Mar; 108(2):251-8. PubMed ID: 17492378
[TBL] [Abstract][Full Text] [Related]
38. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
39. Survivin expression predicts early recurrence in early-stage breast cancer.
Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of p27Kip1 and apoptosis in human breast cancer.
Wu J; Shen ZZ; Lu JS; Jiang M; Han QX; Fontana JA; Barsky SH; Shao ZM
Br J Cancer; 1999 Mar; 79(9-10):1572-8. PubMed ID: 10188908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]